Research Lab Review

Retatrutide’s first phase 3 trials: what 80 weeks of data show

News · Retatrutide

Two phase 3 trials report weight change with retatrutide over 80 weeks, while new reviews raise open questions about side effects and nutrition.

The first peer-reviewed phase 3 results for retatrutide are now out. Retatrutide is an experimental compound that acts on three hormone receptors (GIP, GLP-1 and glucagon) [1, 2]. Two large placebo-controlled trials followed adults with obesity, with or without type 2 diabetes, for 80 weeks [1, 2]. Recent reviews also point to questions that these trials were not designed to answer, including possible nutritional and blood-count effects [3, 4].

Key takeaways

  • In TRIUMPH-1, a randomized, double-blind trial of 2,339 adults with obesity but without diabetes, average weight change at 80 weeks ranged from -17.6% to -25.0% across the retatrutide groups, compared with -3.9% on placebo [1].
  • In TRIUMPH-2, a randomized, double-blind trial of 1,152 adults with obesity and type 2 diabetes, average weight change ranged from -11.9% to -18.8% with retatrutide, compared with -5.1% on placebo [2].
  • Gastrointestinal side effects were the most common in both trials. TRIUMPH-2 also reported more low blood pressure, abnormal skin sensations (dysesthesia) and dropouts due to side effects in the higher-dose groups [1, 2].
  • Both trials compared retatrutide only with placebo and were funded by the manufacturer. A head-to-head trial against semaglutide is registered, but it has not reported results yet [1, 2, 5].

What retatrutide is

Retatrutide activates three receptors at once: those for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon [1]. Older GLP-1 drugs act on one of these receptors. Tirzepatide acts on two. Retatrutide adds the glucagon receptor. A recent scoping review groups it with other “multi-receptor incretin agonists” still in development [3].

In both phase 3 trials, people were randomly assigned to placebo or to one of three retatrutide dose levels [1, 2]. In this article we refer to these as the lower, middle and higher dose groups. The main statistical comparisons were the middle and higher doses against placebo [1, 2].

TRIUMPH-1: adults with obesity, without diabetes

Study type: phase 3, randomized, double-blind, placebo-controlled trial in people; 2,339 participants randomized; 80 weeks [1].

Weight. Average body weight changed by -17.6%, -23.7% and -25.0% in the lower, middle and higher dose groups, compared with -3.9% on placebo [1]. For the middle and higher doses, the differences from placebo were -19.8 and -21.0 percentage points (P<0.001 for both) [1]. These figures use an intention-to-treat style analysis, which counts people who stopped or changed treatment [1].

Knee osteoarthritis subgroup (n=574). Knee pain was measured on a WOMAC scale from 1 to 10, where higher scores mean worse pain [1]. In the trial’s main analysis, scores fell by 3.2 to 3.6 points with retatrutide and by 1.9 points with placebo [1]. For the middle and higher doses, the differences from placebo were -1.6 and -1.8 points [1]. The intention-to-treat analysis gave similar differences of -1.4 and -1.6 points [1]. Pain also fell noticeably in the placebo group, which is common in pain studies [1].

Obstructive sleep apnea subgroup (n=243). The trial measured the apnea-hypopnea index, which counts breathing interruptions per hour of sleep [1]. In the intention-to-treat analysis, events fell by 22.8, 34.3 and 32.1 per hour with retatrutide, compared with 9.6 per hour on placebo [1]. For the middle and higher doses, the differences from placebo were -24.7 and -22.5 events per hour [1]. One figure for the higher dose in the hybrid analysis appears in the abstract without a minus sign. This looks like a typographical error, but we could not confirm it from the abstract alone [1].

Safety. The abstract states that the most common adverse events were gastrointestinal [1]. It does not give rates, discontinuation figures or serious adverse events, so a fuller safety picture needs the full paper [1].

Limits. The comparison was against placebo, not against other approved medicines [1]. The sleep apnea and knee subgroups were much smaller than the full trial [1]. Results beyond 80 weeks were not reported [1]. The trial was funded by the manufacturer [1].

TRIUMPH-2: adults with obesity and type 2 diabetes

Study type: phase 3, randomized, double-blind, placebo-controlled trial at 92 centres in eight countries; 1,152 participants; 80 weeks [2].

Who took part. Participants had an average age of 55, an average BMI of 38.2 kg/m² and an average HbA1c of 7.71% [2]. They had had diabetes for a median of 5.6 years [2]. Most (92%) were already taking oral glucose-lowering medicines [2]. In total, 84% completed the study drug [2].

Weight. Average body weight changed by -11.9%, -16.8% and -18.8% in the lower, middle and higher dose groups, compared with -5.1% on placebo [2]. The differences from placebo were -6.9, -11.8 and -13.8 percentage points (p<0.0001 for all) [2]. The authors also report improvements in blood sugar control, but the abstract does not give those figures [2]. Weight loss was smaller than in TRIUMPH-1 [1, 2]. A similar pattern has been seen with other incretin-based drugs in people with diabetes [3].

Safety. Side effects in the gut were more common with retatrutide [2]:

  • Diarrhoea: 27% to 34% of the retatrutide groups, compared with 13% on placebo [2].
  • Nausea: 14% to 28% of the retatrutide groups, compared with 8% on placebo [2].
  • Low blood pressure (hypotension): up to 6% in the higher dose group, compared with under 1% on placebo [2].
  • Dysesthesia (abnormal or unpleasant skin sensations): 4% to 7% of the retatrutide groups, compared with 1% on placebo [2].
  • Stopping treatment for side effects or death: 12% in the middle dose group and 8% in the higher dose group, compared with 4% in the lower dose group and 5% on placebo [2].

Seven participants died: six across the retatrutide groups and one on placebo [2]. The investigators judged all deaths to be unrelated to the study drug [2].

Limits. As in TRIUMPH-1, the only comparator was placebo, and the manufacturer funded the trial [2]. Participants could take at most three oral diabetes medicines, so the results may not apply to people using insulin [2]. Even within 80 weeks, the higher rate of stopping treatment at the middle dose matters when interpreting the results [2].

What the new reviews add

Scoping review [3]. This review searched PubMed and Scopus in May 2025 and included 41 studies, mostly randomized trials, of anti-obesity medicines [3]. It describes multi-receptor agonists such as retatrutide as having “promising efficacy” [3]. It also reports that gut side effects were the most common across incretin-based drugs [3]. The authors call for comparative trials, mechanistic studies and long-term real-world data [3]. Because the search was run before these phase 3 papers came out, it does not include them [1, 2, 3].

Blood-count review [4]. This narrative review asks whether incretin-based therapies, from gliptins to retatrutide, might contribute to anemia [4]. It suggests several possible routes:

  • eating less food overall [4]
  • a less varied diet [4]
  • gut intolerance [4]
  • slower stomach emptying [4]

These changes could in turn lower levels of iron, vitamin B12, folate, vitamin D, zinc and other nutrients [4]. The evidence comes mainly from observational studies [4]. The authors conclude it is not enough to show a direct cause or an effect across the whole drug class [4]. The review does not present retatrutide-specific blood-count data [4].

What we still don’t know

  • How retatrutide compares with other drugs. Both phase 3 trials used placebo only [1, 2]. TRANSCEND-T2D-2 compares retatrutide with semaglutide in adults with type 2 diabetes. It is listed as active but no longer recruiting, and no results have been posted [5].
  • What happens after 80 weeks. Neither trial reports whether weight change lasts, or what happens after treatment stops [1, 2].
  • Nutrition and blood counts. It is unclear whether large weight loss with retatrutide affects iron, vitamin levels or hemoglobin. The current evidence for incretin drugs is observational and mixed [4].
  • Less common side effects. The higher rates of low blood pressure and dysesthesia in TRIUMPH-2 need longer follow-up and independent study to understand [2].
  • Independent replication. Both trials were funded by the manufacturer. Independent studies and real-world data are still lacking [1, 2, 3].

References

  1. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine (2026). doi:10.1056/NEJMoa2604169
  2. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet (2026). doi:10.1016/S0140-6736(26)01861-1
  3. Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review. Diabetes, Metabolic Syndrome and Obesity (2026). doi:10.2147/DMSO.S626279
  4. The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?. Medical Sciences (2026). doi:10.3390/medsci14050577
  5. Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2). ClinicalTrials.gov NCT06260722, status: active not recruiting.

Image credits

Free to use (CC0 / public domain); credited as a courtesy.

  • L-Glutamic Acid – Space Filling.png, by Small Adjustor (CC0, via wikimedia-commons): source
Open the hub